Algorithm for the Management of MDS

Beta MDS Clear Path

(English/French)

Legacy MDS Clear Path

(English/French)

MDS Clear Path has a new beta version available.

Features include:

An updated MDS treatment algorithm with additional therapy options
Inclusion of molecular- and frailty-based prognostic scoring systems
Updated MDS WHO classification and IWG response criteria
Information on the impact of iron overload and assessment of ESA response

Additional features in our beta version still to come:

Easier menu and content navigation
Tracking of treatment wizard selections within the self-directed mode
MDS Clear Path in French

The content of this program was supported by an unrestricted educational grant from Bristol Myers Squibb (BMS). MDS Clear Path has been developed and approved by a Steering Committee with the input of over 60 Canadian physicians. Members of this Steering Committee are Dr. Heather Leitch, Dr. Harold Olney, Dr. April Shamy, Dr. Brian Leber, and Dr. Richard Wells. The opinions expressed are solely those of the Steering Committee members. The content is specifically intended to be used by qualified physicians/medical professionals, to assist them in the management of MDS patients. The MDS Clear Path does not substitute, nor is it intended to substitute for the medical advice of an appropriately qualified and licensed physician or other healthcare provider. Use of the application is undertaken entirely on your own responsibility as a healthcare professional. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. The digital formats of the MDS Clear Path have been completed by The Adpharm Inc. (a healthcare communications company) through funding from BMS. The sole purpose was to deliver the content of the original MDS Clear Path in a user friendly, digital format. No content was modified in the transition to a digital format. All digital formats are the property of the Canadian Consortium on MDS (CCMDS). This presentation may include indications and treatment regimens that are not authorized in Canada. Please refer to current product monographs for complete indication and safety information.

Welcome!